Login to Your Account

Talon Slides on Briefing Docs Ahead of Marqibo ODAC Panel

By Jennifer Boggs
Managing Editor

Tuesday, March 20, 2012
Shares of Talon Therapeutics Inc. fell 22.7 percent Monday after the FDA released briefing documents ahead of Wednesday's Oncologic Drugs Advisory Committee (ODAC) meeting to discuss a new drug application (NDA) seeking accelerated approval for Marqibo (vincristine sulfate liposomes injection) based on a single-arm study in Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The stock (OTCQB:TLON) lost 22 cents to close at 75 cents.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription